Intestinal methanogenesis

Intestinal methane production is driven predominantly by the methanogenic archaea (such as Methanobrevibacter smithii), which metabolize hydrogen and CO₂ (or other substrates) under anaerobic conditions to produce methane gas in the colon and distal small intestine[1][2][5][6]. This process plays a role in slowing intestinal transit and is epidemiologically linked to symptoms like constipation and IBS-C[2][3][5]. Methane production in the gut can be measured indirectly with breath tests or assessed by quantifying methanogens via stool testing. There is ongoing investigation into its influence on gut motility, metabolic health, and as a potential biomarker for patient stratification and treatment response[1][2][5]. The relevant biological target for drug intervention is not methane per se, but the methanogenic archaea or their metabolic enzymes; antibiotics that suppress these microbes have shown therapeutic benefit in some constipation-predominant bowel disorders[2]. Over-suppression may carry risks due to disruption of the gut’s hydrogen cycle and overall microbial balance[1][3].

Other names

MethanogenesisGut methane productionIntestinal methane production

Antibiotics: Reduction of intestinal methanogen populations leads to decreased methane production and can improve gastrointestinal symptoms (e.g., constipation)